Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + capecitabine in anaplastic thyroid carcinoma
ChiCTR2500113785Phase 2Completed
- Sponsor
- Sichuan Cancer Hospital
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib and capecitabine in anaplastic thyroid cancer (ATC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate. Started Dec 2025; status: completed.
02
Drugs
camrelizumabRivoceranibcapecitabine
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on ChiCTR2500113785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113785.